Page 4 - Jay Mei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antengene Announces Clearance of U S IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Announces Clearance of U S IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bo shanSouth koreaHong kongUnited statesAsia pacificJay meiBing houAntengene corporationHong kong stock exchangeDrug administrationAmerican association for cancer research annual meetingCompany annualPrnewswire antengene corporation limitedAntengene corporation limitedCorporation limitedInvestigational new drug

Antengene Announces Clearance of U S IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.

Bo shanUnited statesSouth koreaJay meiBing houAsia pacificAntengene corporation limitedPrnewswire antengene corporation limitedDrug administrationAmerican association for cancer research annual meetingCorporation limitedInvestigational new drugExecutive directorDrug discoveryChief scientificFamily zhang

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5 6 Times Year-Over-Year and Accelerated Global Innovation

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key.

Hong kongSouth koreaJay meiAsia pacificPeter qianAntengene corporation limitedBank balance to provide runwayCompany annualPrnewswire antengene corporation limitedAntengene corporationHong kong stock exchangeCorporation limitedRevenue reachedAdjusted loss narrowedBest in class potential clinical programsValue drivers

Antengene to Present at the 41st Annual J P Morgan Healthcare Conference

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.

Hong kongUnited statesSouth koreaSan franciscoJay meiAsia pacificPeter qianAntengene investor relations teamCompany annualAntengene corporationBusiness development meetingsHong kong stock exchangeSmall group meetingsPrnewswire antengene corporation limitedAntengene corporation limitedCorporation limited

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSouth koreaJay meiAsia pacificMerck co incCompany annualAntengene corporationMerck sharp dohmeHong kong stock exchangeAntengene corporation limitedFamily zhangChief medicalTreating patients beyond bordersMerck sharpCorporation limited